Atrys Health SL - Asset Resilience Ratio

Latest as of June 2025: 1.20%

Atrys Health SL (ATRY) has an Asset Resilience Ratio of 1.20% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ATRY total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

€6.97 Million

≈ $8.15 Million USD Cash + Short-term Investments

Total Assets

€579.13 Million

≈ $677.07 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2012–2024)

This chart shows how Atrys Health SL's Asset Resilience Ratio has changed over time. See ATRY book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Atrys Health SL's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ATRY market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€6.97 Million	1.2%
Total Liquid Assets	€6.97 Million	1.20%

Asset Resilience Insights

Limited Liquidity: Atrys Health SL maintains only 1.20% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Atrys Health SL Industry Peers by Asset Resilience Ratio

Compare Atrys Health SL's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.10%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	30.29%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	4.52%
Shanghai Junshi Biosciences Co Ltd SHG:688180	Biotechnology	4.28%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	83.49%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	41.74%

Annual Asset Resilience Ratio for Atrys Health SL (2012–2024)

The table below shows the annual Asset Resilience Ratio data for Atrys Health SL.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	1.53%	€8.93 Million ≈ $10.43 Million	€584.19 Million ≈ $682.98 Million	+1.44pp
2023-12-31	0.09%	€554.00K ≈ $647.68K	€629.00 Million ≈ $735.37 Million	-0.16pp
2022-12-31	0.25%	€1.77 Million ≈ $2.07 Million	€705.28 Million ≈ $824.55 Million	-0.91pp
2021-12-31	1.16%	€6.57 Million ≈ $7.68 Million	€565.63 Million ≈ $661.28 Million	-8.86pp
2020-12-31	10.02%	€17.61 Million ≈ $20.59 Million	€175.78 Million ≈ $205.50 Million	+0.07pp
2019-12-31	9.95%	€8.76 Million ≈ $10.24 Million	€88.04 Million ≈ $102.93 Million	-8.51pp
2018-12-31	18.46%	€9.91 Million ≈ $11.59 Million	€53.69 Million ≈ $62.77 Million	+18.11pp
2017-12-31	0.35%	€141.87K ≈ $165.86K	€40.20 Million ≈ $46.99 Million	-0.23pp
2016-12-31	0.59%	€179.05K ≈ $209.33K	€30.57 Million ≈ $35.74 Million	+0.39pp
2015-12-31	0.19%	€50.21K ≈ $58.70K	€26.10 Million ≈ $30.51 Million	-0.06pp
2014-12-31	0.26%	€50.21K ≈ $58.70K	€19.53 Million ≈ $22.83 Million	-1.37pp
2013-12-31	1.63%	€307.64K ≈ $359.67K	€18.87 Million ≈ $22.06 Million	-13.65pp
2012-12-31	15.28%	€2.80 Million ≈ $3.27 Million	€18.29 Million ≈ $21.39 Million	--

pp = percentage points

About Atrys Health SL

MC:ATRY Spain Biotechnology

Market Cap

$249.40 Million

€213.32 Million EUR

Market Cap Rank

#16305 Global

#106 in Spain

Share Price

€2.81

Change (1 day)

-1.23%

52-Week Range

€2.51 - €3.51

All Time High

€11.20